Nuo Therapeutics Inc (AURX)
Nuo Therapeutics, Inc. is a Houston, Texas-based biotechnology company focused on regenerative therapies in the United States. The company develops, commercializes, and markets cell-based technologies designed to support the body’s natural healing processes. Its main product, the Aurix System, separates a patient’s own blood to create a platelet-based treatment used in chronic wound care. Nuo Therapeutics serves hospital outpatient wound care clinics and private practice physicians treating chronic wounds. Founded in 1998, the company was previously known as Cytomedix, Inc. and adopted its current name in November 2014. Its common stock trades on OTC Markets under the symbol AURX.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-AURX
|
$0.85
|
-34.4% Downside
|
Overvalued
|
$3
|
130.8% Upside
|
Bargain
|
Good
|
0.0%
|
December 2, 2026
|
12.1x
|
62.964 M
|
64.325 M
|
2.8%
|
41.9%
|
-9.9
|
121.6%
|
